“There is an urgent need and opportunity to reduce variation to improve patient outcomes” – World Union of Wound Healing Societies.1
“Practice variation has been shown to negatively impact clinical outcomes in patients with chronic wounds,” said Claudia Matei, marketing director for digital health and value-based programs at Smith+Nephew. “Increasingly, we are seeing uninjured specialists managing chronic wounds. With limited training and experience in wound care, this has contributed to significant challenges with practice variation.”2
We developed the WOUND COMPASS clinical support app to help improve nurses’ confidence when assessing and treating wounds,*3 and to provide specialist nurses with assurance that their form is being followed.3
This simple and easy to use application3 categorizes wounds by location on the body, type of wound, appearance of wound, volume of exudate, and depth of wound. Based on this information, this digital health solution provides advice on treatment, products and when to see a specialist. The tips are accompanied by additional educational resources, pictures and diagrams to help with decision-making when treating wounds. The application can also be customized according to the local customer form.
The WOUND COMPASS clinical support app has been tested and validated with over 70 clinicians through over 400 assessments. 83% of non-wound specialists agreed that using the app made wound assessment easier† and the app was recommended by 100% of wound specialists (n=7).3
Clinicians should contact their local Smith+Nephew representative to learn how to implement and customize the WOUND COMPASS Clinic Assist app to suit their form, or to learn more, visit: www.smith-nephew.com/key-products/advanced-wound-management/wound-compass-clinical-support-app-csa. The app works on Apple and Android devices.
*As rated by 58/71 clinicians who assessed self-confidence
† As rated by 59/71 clinicians deemed easier to assess
- World Union of Wound Healing Societies (2020) Strategies to reduce practice variation in wound assessment and management: the TIME clinical decision support tool. London: International Wounds. Available at: www.woundsinternational.com.
- Gray TA, et al. What factors influence community wound care in the UK? A focus group study using the theoretical domains framework. BMJ Open 2019; 9:e024859. doi:10.1136/bmjopen-2018-024859.
- Smith+Nephew 2021. Clinical Support App Pilot Survey Results. Internal report. CSD.AWM.21.002.
Smith+Nephew is a portfolio medical technology company focused on hard and soft tissue repair, regeneration and replacement. We exist to restore people’s bodies and their self-confidence by using technology to push the limits of life. We call this goal ‘Life Unlimited’. Our 18,000 employees carry out this mission every day, making a difference in the lives of patients through the excellence of our product portfolio, as well as the invention and application of new technologies in our three global orthopedics, sports and ENT medicine and advanced wound management franchises.
Founded in Hull, United Kingdomin 1856, we now operate in over 100 countries and generate annual sales of $5.2 billion in 2021. Smith+Nephew is part of the FTSE100 (LSE:SN,NYSE:SNN). The terms “Group” and “Smith+Nephew” are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context otherwise requires.
This document may contain forward-looking statements which may or may not prove to be accurate. For example, statements regarding expected revenue and trading margin growth, market trends and our product portfolio are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well placed”, “believe”, “estimate”, “expect”, “target”, “consider ” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the magnitude and duration of its impact, government actions and other restrictive measures taken in response, significant delays and cancellations elective procedures, reduced procedural capacity at medical facilities, restricted access of sales representatives to medical facilities or our ability to execute business continuity plans due to COVID-19; economic and financial conditions in the markets we serve, particularly those affecting healthcare providers, payers and customers (including, without limitation, due to COVID-19); price levels of established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other governmental actions; product defects or recalls or other issues with quality management systems or non-compliance with related regulations; disputes relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including without limitation as a result of COVID-19); competitions for qualified personnel; strategic actions, including acquisitions and divestitures, our success in performing due diligence, evaluation and integration of acquired businesses; disruptions that may result from transactions or other changes we make to our business plans or organization to adapt to market changes; and many other matters that affect us or our markets, including those of a political, economic, commercial, competitive or reputational nature. Please refer to the documents Smith+Nephew has filed with the United States Securities and Exchange Commission under the United States Securities Exchange Act of 1934, as amended, including Smith+Nephew’s latest annual report on Form 20-F, for a discussion of some of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this cautionary statement. Smith+Nephew undertakes no obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™Trademark of Smith+Nephew. Certain marks are registered in the US Patent and Trademark Office.
SOURCESmith & Nephew plc